The Value of Pharmacogenomic Information
NBER Working Paper No. 24134
Pharmacogenomics, or the application of genetic testing to guide drug selection and/or dosing, is often cited as integral to the vision of how precision medicine can be integrated into routine clinical practice. Yet despite a growing base of scientific discovery on genetic variation that predicts drug response, reimbursement for genetic testing among health systems and payers remains uneven. In large measure this is because the cascading impacts of genetic testing on individual and provider incentives and behavior, as well as downstream health care spending and outcomes, remain poorly understood. In this study, we couple evidence from a real-world implementation of pharmacogenomic testing with a discrete event simulation model. We use this framework to evaluate the cost-effectiveness of various genetic testing strategies. We find that the cost-effectiveness of multiplexed genetic testing (e.g., whole genome sequencing) hinges on the ability of a health system to ensure that dense genotypic information is routinely utilized by physicians. Moreover, while much attention has been paid to lowering the cost of genetic tests, we demonstrate that in practice, other scientific and behavioral factors, focused on certain high-yield drug-gene pairs, are key to implementing precision medicine in ways that maximize its value.
Document Object Identifier (DOI): 10.3386/w24134
Published: The Value of Pharmacogenomic Information, John A. Graves, Zilu Zhou, Shawn Garbett, Josh F. Peterson. in Economic Dimensions of Personalized and Precision Medicine, Berndt, Goldman, and Rowe. 2019
Users who downloaded this paper also downloaded* these: